Novel Regimens in COVID-19 Treatment
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorTanta University
About this trial
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Eligibility criteria
Qualifiers
Patients with COVID-19 infection
Disqualifiers
Allergy or contraindication to the drugs.
Trial design
Treatments tested in this trial
- Nitazoxanide
Treatment groups
160 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov